Microglia at sites of atrophy restrict the progression of retinal degeneration via galectin-3 and Trem2., PMID:38289348
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma., PMID:38372949
sTREM2 Differentially Affects Cytokine Expression in Myeloid-Derived Cell Models via MAPK-JNK Signaling Pathway., PMID:38392305
Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice., PMID:38500108
Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report., PMID:38695172
Microglia, Trem2, and Neurodegeneration., PMID:38769824
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers., PMID:38788719
Mapping Endothelial-Macrophage Interactions in Diabetic Vasculature: Role of TREM2 in Vascular Inflammation and Ischemic Response., PMID:38798611
Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis., PMID:38830764
Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor., PMID:38849345
Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma., PMID:38948071
Multimerization of TREM2 is impaired by Alzheimer's disease-associated variants., PMID:39032157
Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease., PMID:39062786
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?, PMID:39080712
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism., PMID:39090679
Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation., PMID:39149373
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease., PMID:39177331
Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond., PMID:39194679
Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining., PMID:39333507
Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model., PMID:39353433
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies., PMID:39431020
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease., PMID:39434125
Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease., PMID:39444037
Targeting TREM2 signaling shows limited impact on cerebrovascular calcification., PMID:39467636
Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease., PMID:39530260
Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease., PMID:39559879
The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies., PMID:39663111
Soluble TREM2 drives triple-negative breast cancer progression via activation of the AKT pathway., PMID:39672020
Exosomes derived from TREM-2 knocked-out macrophages alleviated renal fibrosis via HSPa1b/AKT pathway., PMID:39657110
A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology., PMID:39676023
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma., PMID:39709141
Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism., PMID:39891235
TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity., PMID:39971937
Biological signatures in the Alzheimer's continuum discriminate between diagnosis-related and -unrelated associations to ATN categories., PMID:40046342
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease., PMID:40050704
Pro-Fibrotic Macrophage Subtypes: SPP1+ Macrophages as a Key Player and Therapeutic Target in Cardiac Fibrosis?, PMID:40072075
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941
IL-33-Induced TREM2+ Macrophages Promote Pathological New Bone Formation Through CREG1-IGF2R Axis in Ankylosing Spondylitis., PMID:40091508
TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy., PMID:40103438
Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination., PMID:40131948
Antibody-induced TREM2 ectodomain shedding inhibits TREM2 signaling in macrophage., PMID:40138757
Choroidal Neovascularization Is Suppressed With Activation of TREM2 in Mononuclear Phagocytes-Brief Report., PMID:40143815
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers., PMID:40166927
The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study., PMID:40353063
Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer´s mouse model., PMID:40405265
Targeted Reprogramming of TREM2-Positive Macrophages and MRI-Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA-Antitrem2 Nanoplatform., PMID:40417930
PET imaging of TREM2 in amyloid-beta induced neuroinflammation., PMID:40434494
Trem2 regulates microglial migratory responses via type I interferon signaling during photoreceptor degeneration., PMID:40468324
TREM2 Hit Discovery Using TRIC Technology: A Proof-of-Concept High-Throughput Screening Approach., PMID:40501992
For research use only. Not for human or drug use.
